The role of biomarkers of acute kidney injury in predicting functional outcomes of surgical treatment of patients with localized kidney cancer

Currently, due to the dynamic development of surgical technologies, indications for organ-sparing treatment of kidney cancer are expanding. Acute kidney injury is a serious complication that leads to chronic kidney disease, increased postoperative mortality, deterioration of long-term functional outcomes, and increased hospitalization. At present, it is known that even a slight damage to kidneys or their impairment, presented by a decreased urine output and change in blood biochemical parameters, entails serious clinical consequences and is associated with a poor prognosis. Damaging factors, when the kidney is exposed, initially induce molecular changes, which entail the production of certain biomarkers, and only after that clinical aspects of kidney damage develop. The causes of acute kidney injury can be different, from specific renal disorders (acute interstitial nephritis, vascular and glomerular lesions, prerenal azotemia, obstructive disorders) to toxic damages, direct trauma and surgical treatment. The development of acute renal injury in the postoperative period is a serious complication of the surgical treatment of kidney disease, and, according to various authors, the frequency of its occurrence varies from 5.5 % to 34 %. An active study of this problem made it possible to find specific biomarkers that give the possibility to predict and diagnose acute renal injury in the early stages, to optimize the treatment strategy, to reduce the incidence of postoperative complications, and to shorten the period of postoperative rehabilitation. Currently, the most studied of acute kidney injury (AKI) biomarkers are cystatin C, neutrophil gelatinase-associated lipocalin‑2 (NGAL), hepatic protein L-FABP, KIM‑1 (Kidney injury molecule‑1), Interleukin – 18. Further study of AKI biomarkers will make it possible to determine the most significant ones for subsequent use in everyday practice

1. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184. https://doi.org/10.1159/000339789

2. Miroshkina IV, Gritskevich AA, Baytman TP, Pyanikin SS, Arevin AG, Kalinin DV, et al. The role of markers of acute kidney damage in assessing kidney function with its ischemia. Experimental and Clinical Urology. 2018;(4):114–121. (In Russian).

3. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006 Aug 15;145(4):237–246. https://doi.org/10.7326/0003-4819-145-4-200608150-00003

4. Chmurzynska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 2006;47(1):39–48. https://doi.org/10.1007/BF03194597

5. Munshi R, Johnson A, Siew ED, Ikizler TA, Ware LB, Wurfel MM, et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol. 2011 Jan;22(1):165–175. https://doi.org/10.1681/ASN.2010060641

6. Andreucci M, Faga T, Pisani A, Perticone M, Michael A. The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice. Eur J Intern Med. 2017 Apr;39:1– 8. https://doi.org/10.1016/j.ejim.2016.12.001

7. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int. 2007 May;71(10):967–970. https://doi.org/10.1038/sj.ki.5002165

8. Kaprin AD, Ivanenko KV, Ivanov SA. Contact ureterolithotripsy by ho laser "MEDILAS H" ("DORNIER"). The Journal of Urology. 2003;(5):43–44. (In Russian).

9. Schmid M, Krishna N, Ravi P, Meyer CP, Becker A, Dalela D, et al. Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urol Oncol. 2016 Jul;34(7):293. e1-293.e10. https://doi.org/10.1016/j.urolonc.2016.02.018

10. Cho A, Lee JE, Kwon G-Y, Huh W, Lee HM, Kim Y-G, et al. Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. Nephrol Dial Transplant. 2011 Nov;26(11):3496–3501. https://doi.org/10.1093/ndt/gfr094

11. Campbell SC, Novick AC, Streem SB, Klein E, Licht M. Complications of nephron sparing surgery for renal tumors. J Urol. 1994 May;151(5):1177–1180. https://doi.org/10.1016/s0022-5347(17)35207-2

12. Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, et al. Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1057–1069. https://doi.org/10.2215/CJN.11941116

13. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993 May 15;268(14):10425–1032.

14. Kjeidsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta. 2000 Oct 18;1482(1–2):272– 283. https://doi.org/10.1016/s0167-4838(00)00152-7

15. Abassi Z, Shalabi A, Sohotnik R, Nativ O, Awad H, Bishara B, et al. Urinary NGAL and KIM-1: biomarkers for assessment of acute ischemic kidney injury following nephron sparing surgery. J Urol. 2013 Apr;189(4):1559–1566. https://doi.org/10.1016/j.juro.2012.10.029

16. Koo KC, Hong JH, Lee HS, Jeh SU, Choi YD, Rha KH, et al. Accuracy of Urinary Neutrophil Gelatinase-Associated Lipocalin in Quantifying Acute Kidney Injury after Partial Nephrectomy in Patients with Normal Contralateral Kidney. PLoS One. 2015;10(7):e0133675. https://doi.org/10.1371/journal.pone.0133675

17. Shalabi A, Nativ O, Sumri M, Bishara B, Khoury W, Awad H, et al. Impact of pneumoperitoneum on the post-operative renal function and level of acute kidney injury markers: comparison between laparoscopic and open nephrectomy. Int Arch Urol Complications. 2017;3(2):1–6. https://doi.org/10.23937/2469-5742/1510026

18. Sprenkle PC, Wren J, Maschino AC, Feifer A, Power N, Ghoneim T, et al. Urine neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after kidney surgery. J Urol. 2013 Jul;190(1):159–164. https://doi.org/10.1016/j.juro.2013.01.101

19. Lahoud Y, Hussein O, Shalabi A, Nativ O, Awad H, Khamaisi M, et al. Effects of phosphodiesterase-5 inhibitor on ischemic kidney injury during nephron sparing surgery: quantitative assessment by NGAL and KIM-1. World J Urol. 2015 Dec;33(12):2053–2062. https://doi.org/10.1007/s00345-015-1579-3

20. Parekh DJ, Weinberg JM, Ercole B, Torkko KC, Hilton W, Bennett M, et al. Tolerance of the human kidney to isolated controlled ischemia. J Am Soc Nephrol. 2013 Feb;24(3):506–517. https://doi.org/10.1681/ASN.2012080786

21. Schmid M, Abd-El-Barr A-E-R, Gandaglia G, Sood A, Olugbade K, Ruhotina N, et al. Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urol Oncol. 2014 Nov;32(8):1259–1266. https://doi.org/10.1016/j.urolonc.2014.05.002

22. Ichimura TT, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998 Feb 13;273(7):4135–4142. https://doi.org/10.1074/jbc.273.7.4135

23. Ismail OZ, Zhang X, Bonventre JV, Gunaratnam L. G protein α12 (Gα12) is a negative regulator of kidney injury molecule-1-mediated efferocytosis. Am J Physiol Renal Physiol. 2016 Apr 1;310(7):F607– F620. https://doi.org/10.1152/ajprenal.00169.2015

24. Solokhina MP, Sergeeva NS, Marshutina NV, Alentov II, Kanukoev KYu, Nyushko KM, et al. KIM-1 as a potential serological/ urinological tumor-associated marker of renal cell carcinoma and chemotherapy nephrotoxicity. Cancer Urology. 2019;15(3):132– 142. (In Russian). https://doi.org/10.17650/1726-9776-2019-15-3-132-142

25. Yin C, Wang N. Kidney injury molecule-1 in kidney disease. Ren Fail. 2016 Nov;38(10):1567–1573. https://doi.org/10.1080/0886022X.2016.1193816

26. Kaseda R, Iino N, Hosojima M, Takeda T, Hosaka K, Kobayashi A, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun. 2007 Jun 15;357(4):1130–1134. https://doi.org/10.1016/j.bbrc.2007.04.072

27. Uchida K, Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta. 2002 Sep;323(1–2):121–128. https://doi.org/10.1016/s0009-8981(02)00177-8

28. Chen J, Lin J, Lin C. Serum and urinary biomarkers for predicting acute kidney injury after partial nephrectomy. Clin Invest Med. 2015 May 31;38(3):E82–E89. https://doi.org/10.25011/cim.v38i3.22703

29. Kit OI, Frantsiyants EM, Dimitriadi SN, Kaplieva IV, Trepitaki LK, Cheryarina ND, et al. Role of markers for acute kidney injury in surgical management of patients with renal cancer. Cancer Urology. 2015;11(3):34–39. (In Russian). https://doi.org/10.17650/1726-9776-2015-11-3-34-39

30. Maatman RG, Van Kuppevelt TH, Veerkamp JH. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J. 1991 Feb 1;273(Pt 3):759–766. https://doi.org/10.1042/bj2730759

31. Tsigou E, Psallida V, Demponeras C, Boutzouka E, Baltopoulos G. Role of new biomarkers: functional and structural damage. Crit Care Res Pract. 2013;2013:361078. https://doi.org/10.1155/2013/361078

32. Frantsiyants EM, Ushakova ND, Kit OI, Rozenko DA, Dimitriadi SN, Shevchenko AN, et al. The Dynamics of Acute Renal Impairment Markers During a Surgery for Kidney Cancer. General Reanimatology. 2017;13(6):38–47. (In Russian). https://doi.org/10.15360/1813-9779-2017-6-38-47

33. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, et al. Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol. 2007 Nov;18(11):2894–902. https://doi.org/10.1681/ASN.2007010097

34. Herget-Rosenthal S, Metzger J, Albalat A, Bitsika V, Mischak H. Proteomic biomarkers for the early detection of acute kidney injury. Prilozi. 2012;33(1):27–48.

35. Slocum JL, Heung M, Pennathur S. Marking renal injury: can we move beyond serum creatinine? Transl Res. 2012 Apr;159(4):277–289. https://doi.org/10.1016/j.trsl.2012.01.014

36. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013 Feb 6;17(1):R25. https://doi.org/10.1186/cc12503

37. FDA News Release: FDA allows marketing of the first test to assess risk of developing acute kidney injury, 2014. Available by: https://www.dicardiology.com/content/fda-allows-marketing-kidney-injury-risk-assessment

38. Sistare FD, Dieterle F, Troth S, Holder DJ, Gerhold D, Andrews-Cleavenger D, et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol. 2010 May;28(5):446–454. https://doi.org/10.1038/nbt.1634

39. Bravi CA, Vertosick E, Benfante N, Tin A, Sjoberg D, HakimiAA, et al. Impact of Acute Kidney Injury and Its Duration on Longterm Renal Function After Partial Nephrectomy. Eur Urol. 2019 Sep;76(3):398–403. https://doi.org/10.1016/j.eururo.2019.04.040

40. Dimitriadi SN, Ushakova ND, Velichko AV, Frantsiyants EM, Rozenko DA. Biomarkers significance in reperfusion-ischemic kidney injury diagnosing as an indication for therapeutic plasmapheresis implementing in patients with localised renal cancer after partial nephrectomy under conditions of warm ischemia. Modern problems of science and education. 2019;(4):57. (In Russian).